Acasti Pharma Inc. (ACST)
- Previous Close
3.2100 - Open
3.2100 - Bid --
- Ask --
- Day's Range
3.0600 - 3.2219 - 52 Week Range
1.7200 - 3.8400 - Volume
12,341 - Avg. Volume
20,531 - Market Cap (intraday)
28.762M - Beta (5Y Monthly) 1.62
- PE Ratio (TTM)
-- - EPS (TTM)
-5.6800 - Earnings Date Jun 21, 2024 - Jun 25, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.01
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
www.acastipharma.comRecent News: ACST
Performance Overview: ACST
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACST
Valuation Measures
Market Cap
28.76M
Enterprise Value
3.67M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.44
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-7.92%
Return on Equity (ttm)
-48.05%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-38.77M
Diluted EPS (ttm)
-5.6800
Balance Sheet and Cash Flow
Total Cash (mrq)
25.11M
Total Debt/Equity (mrq)
0.04%
Levered Free Cash Flow (ttm)
-7.84M